Preferred Label : Relugolix;
NCIt synonyms : N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea; Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-;
NCIt definition : An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing
hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity.
Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary
gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion
and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH).
In males, the inhibition of LH secretion prevents the release of testosterone from
Leydig cells in the testes. Since testosterone is required to sustain prostate growth,
reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.;
UNII : P76B05O5V6;
CAS number : 737789-87-6;
Drug name : Orgovyx; Relumina;
Molecule name : TAK 385; TAK-385;
Codes from synonyms : 18352;
Origin ID : C114498;
UMLS CUI : C3896936;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
